Immunotherapy plus TACE vs. Targeted Therapy plus TACE for Advanced Liver Cancer
Part of Cancer clinical trials.
This trial is testing a combination of two immunotherapy drugs (sintilimab and bevacizumab) plus a procedure called TACE (chemoembolization) against a targeted therapy pill (lenvatinib) plus TACE for people with advanced liver cancer. The goal is to see which approach works better to shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer (stage C) that can be treated with a procedure called TACE (chemoembolization).
- You have not had any previous treatment for your liver cancer, such as pills, infusions, or procedures like TACE or radiation.
- Your liver is working well (Child-Pugh class A), and you are able to do daily activities without help (ECOG 0 or 1).
- You have not had any serious bleeding, blood clots, or major surgery in the recent past.
- You do not have active infections like tuberculosis, HIV, or uncontrolled hepatitis B or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a stronger treatment plan (lenvatinib plus sintilimab plus TACE) against a standard plan (lenvatinib plus TACE) for advanced liver cancer. It aims to see which plan works better to control tumors and help patients live longer.
This trial tests a combination of blood-vessel–targeting medicine and immunotherapy after a liver-directed treatment called TACE for advanced hepatocellular carcinoma (HCC). It aims to control tumor growth when surgery or ablation isn’t suitable, and to see if this “conversion therapy” helps patients do better than standard pathways.
This study tests combining TACE (a procedure to block the tumor's blood supply) with immunotherapy drugs for liver cancer that has not spread outside the liver. It is for people who have not had any prior treatment for their liver cancer and are healthy enough for TACE.
This Phase 2 trial tests whether starting with atezolizumab plus bevacizumab, then using an on-demand TACE (a targeted liver artery chemo treatment) can control hepatocellular carcinoma (liver cancer). It also compares this approach to giving both medicines together with an initial TACE right away, aiming to improve tumor control and outcomes.
This trial tests a combination of two drugs (bevacizumab and sintilimab) versus a standard procedure (TACE) for people with intermediate-stage liver cancer that is too large or widespread for surgery. The goal is to see if the drug combination works better at controlling the cancer.
This Phase 3 trial tests whether combining several treatments—SBRT (targeted radiation), lenvatinib (an oral anti-cancer medicine), and TACE (a procedure that blocks blood supply to the tumor)—can work better for people with advanced primary liver cancer. It may help shrink tumors and improve survival compared with standard approaches.
Hear when a new Hepatocellular Carcinoma Non-resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.